Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc. (SGHT) pioneers transformative ophthalmic devices for glaucoma and dry eye treatment, merging surgical precision with evidence-based therapeutic solutions. This page serves as the definitive source for SGHT-related news, offering stakeholders timely updates on advancements shaping eye care innovation.
Access press releases, clinical trial results, and regulatory milestones covering minimally invasive glaucoma surgery (MIGS) technologies like the OMNI Surgical System and the TearCare System for dry eye management. Our curated collection ensures professionals and investors stay informed about product approvals, peer-reviewed research, and strategic partnerships driving the company’s growth.
Explore updates across key areas including surgical device innovations, real-world clinical data, and regulatory filings. Each announcement is vetted for relevance, providing actionable insights into SGHT’s market position and technological leadership in interventional eyecare.
Bookmark this page for streamlined access to Sight Sciences’ latest developments. Regularly updated with authoritative content, it empowers users to track progress in ophthalmic treatment solutions backed by clinical validation and engineering excellence.
Sight Sciences, Inc. (Nasdaq: SGHT) reported robust financial results for Q2 2022, achieving total revenue of $17.2 million, a 37% increase from the previous year. The company expanded its gross margin to 84% and reported a 33% rise in Surgical Glaucoma revenue, totaling $15.9 million. Operating expenses rose to $37.4 million, significantly impacting net loss, which grew to $23.8 million ($0.50 per share). Looking ahead, Sight Sciences projects 2022 revenue between $68 million and $72 million, marking an anticipated growth of 39% to 47% compared to 2021.
Sight Sciences (Nasdaq: SGHT) will release its Q2 2022 financial results on August 11, 2022, after market close. A conference call discussing the results is scheduled for 1:30 p.m. PT / 4:30 p.m. ET. Investors are encouraged to register for the audio webcast and will have access to a replay via the investor relations website. The company specializes in eyecare technology, aiming to improve care for prevalent eye diseases with innovative, minimally invasive solutions.
Sight Sciences, Inc. (Nasdaq: SGHT) has announced the appointment of Tamara Fountain, M.D., to its Board of Directors, effective July 15, 2022. Dr. Fountain brings extensive ophthalmic experience, having served as President of the American Academy of Ophthalmology in 2021 and currently on the Board of the American Board of Ophthalmology. Her expertise is expected to enhance Sight Sciences' efforts in glaucoma and ocular surface disease, fostering partnerships within the ophthalmic community. The company continues to focus on innovative solutions for eye care, including its OMNI® Surgical System and TearCare® System.
Sight Sciences, Inc. (SGHT) announced positive results from the GEMINI study, demonstrating that its OMNI Surgical System effectively reduces unmedicated diurnal intraocular pressure (IOP) in open-angle glaucoma patients when combined with cataract surgery. The study revealed a mean IOP reduction of 35% at 12 months, with 84.2% of eyes achieving over 20% reduction. Notably, in a Hispanic subset, IOP decreased from 22.8 mmHg to 14.9 mmHg, with 87% requiring no medications. These findings underscore the significance of the OMNI system in glaucoma treatment, especially for demographics at higher risk.
Sight Sciences, Inc. (Nasdaq: SGHT) has announced its participation in the Piper Sandler Virtual Ophthalmology & Diabetes Symposium scheduled for May 23, 2022, at 10:00 AM PT. This event will feature a fireside chat with the company's management, accessible via webcast on their investor website. Sight Sciences is dedicated to innovating eyecare solutions to improve patient treatment, particularly through its OMNI® Surgical System for glaucoma and TearCare® System for dry eye disease, both aimed at enhancing patient care and addressing significant eye health challenges.
Sight Sciences, Inc. (Nasdaq: SGHT) reported strong financial results for Q1 2022, with total revenue of $14.9 million, marking a 72% increase year-over-year. Surgical Glaucoma revenue rose 70% to $13.9 million, while Dry Eye revenue surged 104% to $1.0 million. The gross profit reached $11.8 million with an 80% gross margin, up from 73% last year. However, operating expenses jumped 89% to $34.0 million, resulting in a net loss of $23.3 million. The company expects full-year 2022 revenue between $67 million and $75 million, reflecting a 37% to 53% growth.
Sight Sciences, a leader in eyecare technology, announced participation in the Bank of America Healthcare Conference scheduled for May 12, 2022, at 9:20 am PT. The event will showcase the company's innovative solutions aimed at enhancing patient care, including the OMNI® Surgical System and TearCare® System, which target prevalent eye diseases. Interested investors can access the live and archived webcast on the company’s Investors page on their website. This initiative underscores the company’s commitment to transforming eyecare.
Sight Sciences, Inc. (Nasdaq: SGHT) announced that data on the OMNI® Surgical System will be presented at the 2022 ASCRS Annual Meeting from April 22-26. The company will also sponsor a MIGS education symposium on April 22. Three posters will be presented, covering outcomes of canaloplasty and trabeculotomy, IOP fluctuations, and combined cataract surgery outcomes in Hispanic patients. Sight Sciences aims to transform eyecare through innovative solutions and is focused on minimally invasive techniques addressing leading causes of eye diseases.
Sight Sciences, Inc. (Nasdaq: SGHT) announced it will report financial results for Q1 2022 on May 10, 2022, after market close. Management will hold a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The company focuses on innovative eyecare solutions like the OMNI® Surgical System and TearCare® System, targeting prevalent eye diseases. Interested investors can access the call through their website or via dial-in options. These systems provide minimally invasive treatments for conditions like glaucoma and dry eye disease.
Sight Sciences, Inc. (Nasdaq: SGHT) reported strong financial results for 2021, achieving $49.0 million in total revenue, a 77% increase from the previous year. Fourth-quarter revenue was $14.7 million, up 63%. Gross margins expanded to 87% compared to 74% in Q4 2020. The company received FDA clearance for the TearCare® System and published significant clinical data supporting the OMNI® Surgical System. Operating expenses surged to $91.8 million in 2021, resulting in a net loss of $63.0 million. Guidance for 2022 projects revenue between $67 million and $75 million.
